Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Health

    Green signal for first stem cell therapy, novel HIV drug

    By WANG XIAOYU | chinadaily.com.cn | Updated: 2025-01-03 21:34
    Share
    Share - WeChat

    China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication associated with bone marrow transplant, as well as a novel HIV drug that only requires two shots yearly.

    The National Medical Products Administration said on Thursday that it granted conditional approval to an injection from the domestic drugmaker Platinum Life to treat patients aged 14 and above who suffer a rare disease called acute graft-versus-host disease and do not respond to regular steroid therapy.

    Acute graft-versus-host disease, or aGVHD, typically hits patients who have just undergone a stem cell transplant due to severe blood condition. The disease is one of the primary reasons of death following transplantation.

    The homegrown therapy is the first mesenchymal stromal cell treatment that has gained the greenlight on the Chinese mainland. The approval was issued through an accelerated market registration track designed for novel or urgently needed medicines.

    Stem cell therapy utilizes the differentiation and self-renewal capacity of stem cells to repair tissues and treat diseases. It represents a booming research field being studied worldwide to treat a variety of illnesses, including diabetes, Parkinson's disease and cancer.

    In China, the nation's first drug manufacturing license for stem cell treatment was issued in late May by the Beijing Municipal Medical Products Administration to Platinum Life.

    Chen Jiekai, a researcher at Chinese Academy of Sciences' Guangzhou Institutes of Biomedicine and Health, said that the issue of the license constitutes a key step toward clinical applications of stem cell treatment and signals the establishment of a complete supervision procedure for this kind of novel therapy.

    During an academic conference held in Guangzhou, Guangdong province in early December, he said that there are hundreds of clinical research projects on stem cell treatment across the nation, and a total of 141 hospitals have registered with a national medical research platform in preparation for carrying out stem cell clinical studies, local media reported.

    Also on Thursday, China approved lenacapavir, a long-acting HIV drug made by global biopharmaceutical company Gilead Sciences, according to the administration and the company.

    The treatment is approved to treat HIV patients who have multidrug resistance and cannot have their viral load effectively suppressed under available drug regimens.

    It was first approved in Europe and the United States in 2022, and research is underway to test its potential in preventing infection.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    亚洲VA中文字幕不卡无码| 亚洲国产av无码精品| 日韩va中文字幕无码电影| 亚洲AV无码乱码在线观看富二代 | 天堂中文8资源在线8| 久久久久亚洲?V成人无码| 亚洲AV无码专区国产乱码电影| www.中文字幕| 高清无码中文字幕在线观看视频| 精品无码国产污污污免费网站| 久久久久亚洲AV无码专区首JN| 中文字幕日韩精品无码内射| 成人无码免费一区二区三区 | 人妻丰满熟妇AV无码区乱| 中文精品久久久久人妻| 欧美视频中文字幕| 日本中文字幕在线| 无码不卡亚洲成?人片| WWW插插插无码视频网站| 2024最新热播日韩无码| 国产亚洲3p无码一区二区| 无码性午夜视频在线观看| 亚洲精品~无码抽插| 国产成人无码AV一区二区| 日韩精品无码人妻一区二区三区| 中文字幕在线观看亚洲日韩| 中文字幕免费在线| 日本高清不卡中文字幕免费| 欧美中文字幕在线视频| 天堂8а√中文在线官网| 欧美日韩中文国产一区| 最好看的中文字幕2019免费| 久久丝袜精品中文字幕| 性无码专区一色吊丝中文字幕| 免费无码国产在线观国内自拍中文字幕| 无码超乳爆乳中文字幕久久| 台湾佬中文娱乐中文| 再看日本中文字幕在线观看| 无码夫の前で人妻を侵犯| 亚洲AV无码专区国产乱码电影 | 久久亚洲AV成人出白浆无码国产|